{"id":"thioguanine","rwe":[],"_fda":{"id":"120a3a37-e84a-406b-94f8-243897706dc6","set_id":"44b0c461-47fb-4106-ba11-6ed85530235c","openfda":{"unii":["FTK8U1GZNX"],"route":["ORAL"],"rxcui":["105590","198269"],"spl_id":["120a3a37-e84a-406b-94f8-243897706dc6"],"brand_name":["TABLOID"],"spl_set_id":["44b0c461-47fb-4106-ba11-6ed85530235c"],"package_ndc":["80725-630-25"],"product_ndc":["80725-630"],"generic_name":["THIOGUANINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["THIOGUANINE"],"manufacturer_name":["Waylis Therapeutics LLC"],"application_number":["NDA012429"],"is_original_packager":[true]},"version":"3","warnings":["WARNINGS SINCE DRUGS USED IN CANCER CHEMOTHERAPY ARE POTENTIALLY HAZARDOUS, IT IS RECOMMENDED THAT ONLY PHYSICIANS EXPERIENCED WITH THE RISKS OF THIOGUANINE AND KNOWLEDGEABLE IN THE NATURAL HISTORY OF ACUTE NONLYMPHOCYTIC LEUKEMIAS ADMINISTER THIS DRUG. THIOGUANINE IS NOT RECOMMENDED FOR MAINTENANCE THERAPY OR SIMILAR LONG-TERM CONTINUOUS TREATMENTS DUE TO THE HIGH RISK OF LIVER TOXICITY ASSOCIATED WITH VASCULAR ENDOTHELIAL DAMAGE (see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS). This liver toxicity has been observed in a high proportion of children receiving thioguanine as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use of thioguanine. This liver toxicity is particularly prevalent in males. Liver toxicity usually presents as the clinical syndrome of hepatic veno-occlusive disease (hyperbilirubinemia, tender hepatomegaly, weight gain due to fluid retention, and ascites) or with signs of portal hypertension (splenomegaly, thrombocytopenia, and oesophageal varices). Histopathological features associated with this toxicity include hepatoportal sclerosis, nodular regenerative hyperplasia, peliosis hepatitis, and periportal fibrosis. Thioguanine therapy should be discontinued in patients with evidence of liver toxicity as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Patients must be carefully monitored (see PRECAUTIONS, Laboratory Tests). Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported in association with liver toxicity but do not always occur. The most consistent, dose-related toxicity is bone marrow suppression. This may be manifested by anemia, leukopenia, thrombocytopenia, or any combination of these. Any one of these findings may also reflect progression of the underlying disease. Since thioguanine may have a delayed effect, it is important to withdraw the medication temporarily at the first sign of an abnormally large fall in any of the formed elements of the blood. There are individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) who may be unusually sensitive to the myelosuppressive effects of thioguanine and prone to developing rapid bone marrow suppression following the initiation of treatment. Substantial dosage reductions may be required to avoid the development of life-threatening bone marrow suppression in these patients. Prescribers should be aware that some laboratories offer testing for TPMT deficiency. Since bone marrow suppression may be associated with factors other than TPMT deficiency, TPMT testing may not identify all patients at risk for severe toxicity. Therefore, close monitoring of clinical and hematologic parameters is important. Bone marrow suppression could be exacerbated by coadministration with drugs that inhibit TPMT, such as olsalazine, mesalazine, or sulphasalazine. It is recommended that evaluation of the hemoglobin concentration or hematocrit, total white blood cell count and differential count, and quantitative platelet count be obtained frequently while the patient is on thioguanine therapy. In cases where the cause of fluctuations in the formed elements in the peripheral blood is obscure, bone marrow examination may be useful for the evaluation of marrow status. The decision to increase, decrease, continue, or discontinue a given dosage of thioguanine must be based not only on the absolute hematologic values, but also upon the rapidity with which changes are occurring. In many instances, particularly during the induction phase of acute leukemia, complete blood counts will need to be done more frequently in order to evaluate the effect of the therapy. The dosage of thioguanine may need to be reduced when this agent is combined with other drugs whose primary toxicity is myelosuppression. Myelosuppression is often unavoidable during the induction phase of adult acute nonlymphocytic leukemias if remission induction is to be successful. Whether or not this demands modification or cessation of dosage depends both upon the response of the underlying disease and a careful consideration of supportive facilities (granulocyte and platelet transfusions) which may be available. Life-threatening infections and bleeding have been observed as consequences of thioguanine-induced granulocytopenia and thrombocytopenia. The effect of thioguanine on the immunocompetence of patients is unknown. Pregnancy Drugs such as thioguanine are potential mutagens and teratogens. Thioguanine may cause fetal harm when administered to a pregnant woman. Thioguanine has been shown to be teratogenic in rats when given in doses 5 times the human dose. When given to the rat on the 4th and 5th days of gestation, 13% of surviving placentas did not contain fetuses, and 19% of offspring were malformed or stunted. The malformations noted included generalized edema, cranial defects, and general skeletal hypoplasia, hydrocephalus, ventral hernia, situs inversus, and incomplete development of the limbs. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant."],"pregnancy":["Pregnancy Drugs such as thioguanine are potential mutagens and teratogens. Thioguanine may cause fetal harm when administered to a pregnant woman. Thioguanine has been shown to be teratogenic in rats when given in doses 5 times the human dose. When given to the rat on the 4th and 5th days of gestation, 13% of surviving placentas did not contain fetuses, and 19% of offspring were malformed or stunted. The malformations noted included generalized edema, cranial defects, and general skeletal hypoplasia, hydrocephalus, ventral hernia, situs inversus, and incomplete development of the limbs. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.","Pregnancy Teratogenic Effects: See WARNINGS section."],"overdosage":["OVERDOSAGE Signs and symptoms of overdosage may be immediate, such as nausea, vomiting, malaise, hypotension, and diaphoresis; or delayed, such as myelosuppression and azotemia. It is not known whether thioguanine is dialyzable. Hemodialysis is thought to be of marginal use due to the rapid intracellular incorporation of thioguanine into active metabolites with long persistence. The oral LD 50 of thioguanine was determined to be 823 mg/kg ± 50.73 mg/kg and 740 mg/kg ± 45.24 mg/kg for male and female rats, respectively. Symptoms of overdosage may occur after a single dose of as little as 2.0 to 3.0 mg/kg thioguanine. As much as 35 mg/kg has been given in a single oral dose with reversible myelosuppression observed. There is no known pharmacologic antagonist of thioguanine. The drug should be discontinued immediately if unintended toxicity occurs during treatment. Severe hematologic toxicity may require supportive therapy with platelet transfusions for bleeding, and granulocyte transfusions and antibiotics if sepsis is documented. If a patient is seen immediately following an accidental overdosage of the drug, it may be useful to induce emesis."],"references":["REFERENCES 1. ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society; 1999:32-41. 2. Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety, Clinical Center Pharmacy Department and Cancer Nursing Services, National Institutes of Health and Human Services, 1992, US Dept of Health and Human Services, Public Health Service publication NIH 92-2621. 3. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985;253:1590-1591. 4. National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115. 5. Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia. 1983;1:426-428. 6. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. CA-A Cancer J for Clin . 1983;33:258-263. 7. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033-1049. 8. Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines.) Am J Health- Syst Pharm. 1996;53:1669-1685. Distributed by: Waylis Therapeutics LLC Wixom, MI 48393 Made in Germany Rev. 02/2023 Waylis Logo"],"description":["DESCRIPTION TABLOID brand Thioguanine was synthesized and developed by Hitchings, Elion, and associates at the Wellcome Research Laboratories. It is one of a large series of purine analogues which interfere with nucleic acid biosynthesis and has been found active against selected human neoplastic diseases. Thioguanine, known chemically as 2-amino-1,7-dihydro-6 H -purine-6-thione, is an analogue of the nucleic acid constituent guanine, and is closely related structurally and functionally to PURINETHOL ® (mercaptopurine). Its structural formula is: TABLOID brand Thioguanine is available in tablets for oral administration. Each scored tablet contains 40 mg thioguanine and the inactive ingredients acacia, lactose monohydrate, magnesium stearate, potato starch, and stearic acid. thioguanine chemical structure"],"precautions":["PRECAUTIONS General Although the primary toxicity of thioguanine is myelosuppression, other toxicities have occasionally been observed, particularly when thioguanine is used in combination with other cancer chemotherapeutic agents. A few cases of jaundice have been reported in patients with leukemia receiving thioguanine. Among these were 2 adult male patients and 4 pediatric patients with acute myelogenous leukemia and an adult male with acute lymphocytic leukemia who developed hepatic veno-occlusive disease while receiving chemotherapy for their leukemia. Six patients had received cytarabine prior to treatment with thioguanine, and some were receiving other chemotherapy in addition to thioguanine when they became symptomatic. While hepatic veno-occlusive disease has not been reported in patients treated with thioguanine alone, it is recommended that thioguanine be withheld if there is evidence of toxic hepatitis or biliary stasis, and that appropriate clinical and laboratory investigations be initiated to establish the etiology of the hepatic dysfunction. Deterioration in liver function studies during thioguanine therapy should prompt discontinuation of treatment and a search for an explanation of the hepatotoxicity. Administration of live vaccines to immunocompromised patients should be avoided. Information for Patients Patients should be informed that the major toxicities of thioguanine are related to myelosuppression, hepatotoxicity, and gastrointestinal toxicity. Patients should never be allowed to take the drug without medical supervision and should be advised to consult their physician if they experience fever, sore throat, jaundice, nausea, vomiting, signs of local infection, bleeding from any site, or symptoms suggestive of anemia. Women of childbearing potential should be advised to avoid becoming pregnant. Laboratory Tests Prescribers should be aware that some laboratories offer testing for TPMT deficiency (see WARNINGS). It is advisable to monitor liver function tests (serum transaminases, alkaline phosphatase, bilirubin) at weekly intervals when first beginning therapy and at monthly intervals thereafter. It may be advisable to perform liver function tests more frequently in patients with known pre-existing liver disease or in patients who are receiving thioguanine and other hepatotoxic drugs. Patients should be instructed to discontinue thioguanine immediately if clinical jaundice is detected (see WARNINGS). Drug Interactions There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy (see WARNINGS). Carcinogenesis, Mutagenesis, Impairment of Fertility In view of its action on cellular DNA, thioguanine is potentially mutagenic and carcinogenic, and consideration should be given to the theoretical risk of carcinogenesis when thioguanine is administered (see WARNINGS). Pregnancy Teratogenic Effects: See WARNINGS section. Lactation It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for thioguanine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use See DOSAGE AND ADMINISTRATION section. Geriatric Use Clinical studies of thioguanine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED A biconvex, round white to off-white tablet, one side imprinted T40 and with a scorebar and the other side plain: in bottles of 25 tablets (NDC 80725-630-25). Store at 15° to 25°C (59° to 77°F) in a dry place."],"geriatric_use":["Geriatric Use Clinical studies of thioguanine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use See DOSAGE AND ADMINISTRATION section."],"effective_time":"20250108","nursing_mothers":["Lactation It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for thioguanine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"laboratory_tests":["Laboratory Tests Prescribers should be aware that some laboratories offer testing for TPMT deficiency (see WARNINGS). It is advisable to monitor liver function tests (serum transaminases, alkaline phosphatase, bilirubin) at weekly intervals when first beginning therapy and at monthly intervals thereafter. It may be advisable to perform liver function tests more frequently in patients with known pre-existing liver disease or in patients who are receiving thioguanine and other hepatotoxic drugs. Patients should be instructed to discontinue thioguanine immediately if clinical jaundice is detected (see WARNINGS)."],"adverse_reactions":["ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Waylis Therapeutics LLC Toll-Free at 1-888-514-4727 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The most frequent adverse reaction to thioguanine is myelosuppression. The induction of complete remission of acute myelogenous leukemia usually requires combination chemotherapy in dosages which produce marrow hypoplasia. Since consolidation and maintenance of remission are also effected by multiple-drug regimens whose component agents cause myelosuppression, pancytopenia is observed in nearly all patients. Dosages and schedules must be adjusted to prevent life-threatening cytopenias whenever these adverse reactions are observed. Hyperuricemia frequently occurs in patients receiving thioguanine as a consequence of rapid cell lysis accompanying the antineoplastic effect. Adverse effects can be minimized by increased hydration, urine alkalinization, and the prophylactic administration of a xanthine oxidase inhibitor such as ZYLOPRIM ® (allopurinol). Unlike PURINETHOL (mercaptopurine) and IMURAN ® (azathioprine), thioguanine may be continued in the usual dosage when allopurinol is used conjointly to inhibit uric acid formation. Less frequent adverse reactions include nausea, vomiting, anorexia, and stomatitis. Intestinal necrosis and perforation have been reported in patients who received multiple-drug chemotherapy including thioguanine. Hepatic Effects Liver toxicity associated with vascular endothelial damage has been reported when thioguanine is used in maintenance or similar long-term continuous therapy which is not recommended (see WARNINGS and DOSAGE AND ADMINISTRATION). This usually presents as the clinical syndrome of hepatic veno-occlusive disease (hyperbilirubinemia, tender hepatomegaly, weight gain due to fluid retention, and ascites) or signs and symptoms of portal hypertension (splenomegaly, thrombocytopenia, and esophageal varices). Elevation of liver transaminases, alkaline phosphatase, and gamma glutamyl transferase and jaundice may also occur. Histopathological features associated with this toxicity include hepatoportal sclerosis, nodular regenerative hyperplasia, peliosis hepatitis, and periportal fibrosis. Liver toxicity during short-term cyclical therapy presents as veno-occlusive disease. Reversal of signs and symptoms of this liver toxicity has been reported upon withdrawal of short-term or long-term continuous therapy. Centrilobular hepatic necrosis has been reported in a few cases; however, the reports are confounded by the use of high doses of thioguanine, other chemotherapeutic agents, and oral contraceptives and chronic alcohol abuse."],"contraindications":["CONTRAINDICATIONS Thioguanine should not be used in patients whose disease has demonstrated prior resistance to this drug. In animals and humans, there is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine."],"drug_interactions":["Drug Interactions There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy (see WARNINGS)."],"general_precautions":["General Although the primary toxicity of thioguanine is myelosuppression, other toxicities have occasionally been observed, particularly when thioguanine is used in combination with other cancer chemotherapeutic agents. A few cases of jaundice have been reported in patients with leukemia receiving thioguanine. Among these were 2 adult male patients and 4 pediatric patients with acute myelogenous leukemia and an adult male with acute lymphocytic leukemia who developed hepatic veno-occlusive disease while receiving chemotherapy for their leukemia. Six patients had received cytarabine prior to treatment with thioguanine, and some were receiving other chemotherapy in addition to thioguanine when they became symptomatic. While hepatic veno-occlusive disease has not been reported in patients treated with thioguanine alone, it is recommended that thioguanine be withheld if there is evidence of toxic hepatitis or biliary stasis, and that appropriate clinical and laboratory investigations be initiated to establish the etiology of the hepatic dysfunction. Deterioration in liver function studies during thioguanine therapy should prompt discontinuation of treatment and a search for an explanation of the hepatotoxicity. Administration of live vaccines to immunocompromised patients should be avoided."],"teratogenic_effects":["Teratogenic Effects: See WARNINGS section."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Clinical studies have shown that the absorption of an oral dose of thioguanine in humans is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%). Following oral administration of 35 S-6-thioguanine, total plasma radioactivity reached a maximum at 8 hours and declined slowly thereafter. Parent drug represented only a very small fraction of the total plasma radioactivity at any time, being virtually undetectable throughout the period of measurements. The oral administration of radiolabeled thioguanine revealed only trace quantities of parent drug in the urine. However, a methylated metabolite, 2-amino-6-methylthiopurine (MTG), appeared very early, rose to a maximum 6 to 8 hours after drug administration, and was still being excreted after 12 to 22 hours. Radiolabeled sulfate appeared somewhat later than MTG but was the principal metabolite after 8 hours. Thiouric acid and some unidentified products were found in the urine in small amounts. Intravenous administration of 35 S-6-thioguanine disclosed a median plasma half-disappearance time of 80 minutes (range: 25 to 240 minutes) when the compound was given in single doses of 65 to 300 mg/m 2 . Although initial plasma levels of thioguanine did correlate with the dose level, there was no correlation between the plasma half-disappearance time and the dose. Thioguanine is incorporated into the DNA and the RNA of human bone marrow cells. Studies with intravenous 35 S-6-thioguanine have shown that the amount of thioguanine incorporated into nucleic acids is more than 100 times higher after 5 daily doses than after a single dose. With the 5-dose schedule, from one-half to virtually all of the guanine in the residual DNA was replaced by thioguanine. Tissue distribution studies of 35 S-6-thioguanine in mice showed only traces of radioactivity in brain after oral administration. No measurements have been made of thioguanine concentrations in human cerebrospinal fluid (CSF), but observations on tissue distribution in animals, together with the lack of CNS penetration by the closely related compound, mercaptopurine, suggest that thioguanine does not reach therapeutic concentrations in the CSF. Monitoring of plasma levels of thioguanine during therapy is of questionable value. There is technical difficulty in determining plasma concentrations, which are seldom greater than 1 to 2 mcg/mL after a therapeutic oral dose. More significantly, thioguanine enters rapidly into the anabolic and catabolic pathways for purines, and the active intracellular metabolites have appreciably longer half-lives than the parent drug. The biochemical effects of a single dose of thioguanine are evident long after the parent drug has disappeared from plasma. Because of this rapid metabolism of thioguanine to active intracellular derivatives, hemodialysis would not be expected to appreciably reduce toxicity of the drug. Thioguanine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to 6-thioguanylic acid (TGMP). This nucleotide reaches high intracellular concentrations at therapeutic doses. TGMP interferes at several points with the synthesis of guanine nucleotides. It inhibits de novo purine biosynthesis by pseudo-feedback inhibition of glutamine-5-phosphoribosylpyrophosphate amidotransferase—the first enzyme unique to the de novo pathway for purine ribonucleotide synthesis. TGMP also inhibits the conversion of inosinic acid (IMP) to xanthylic acid (XMP) by competition for the enzyme IMP dehydrogenase. At one time TGMP was felt to be a significant inhibitor of ATP:GMP phosphotransferase (guanylate kinase), but recent results have shown this not to be so. Thioguanylic acid is further converted to the di- and tri-phosphates, thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP) (as well as their 2′-deoxyribosyl analogues) by the same enzymes which metabolize guanine nucleotides. Thioguanine nucleotides are incorporated into both the RNA and the DNA by phosphodiester linkages and it has been argued that incorporation of such fraudulent bases contributes to the cytotoxicity of thioguanine. Thus, thioguanine has multiple metabolic effects and at present it is not possible to designate one major site of action. Its tumor inhibitory properties may be due to one or more of its effects on (a) feedback inhibition of de novo purine synthesis; (b) inhibition of purine nucleotide interconversions; or (c) incorporation into the DNA and the RNA. The net consequence of its actions is a sequential blockade of the synthesis and utilization of the purine nucleotides. The catabolism of thioguanine and its metabolites is complex and shows significant differences between humans and the mouse. In both humans and mice, after oral administration of 35 S-6-thioguanine, urine contains virtually no detectable intact thioguanine. While deamination and subsequent oxidation to thiouric acid occurs only to a small extent in humans, it is the main pathway in mice. The product of deamination by guanase, 6-thioxanthine is inactive, having negligible antitumor activity. This pathway of thioguanine inactivation is not dependent on the action of xanthine oxidase, and an inhibitor of that enzyme (such as allopurinol) will not block the detoxification of thioguanine even though the inactive 6-thioxanthine is normally further oxidized by xanthine oxidase to thiouric acid before it is eliminated. In humans, methylation of thioguanine is much more extensive than in the mouse. The product of methylation, 2-amino-6-methylthiopurine, is also substantially less active and less toxic than thioguanine and its formation is likewise unaffected by the presence of allopurinol. Appreciable amounts of inorganic sulfate are also found in both murine and human urine, presumably arising from further metabolism of the methylated derivatives. In some animal tumors, resistance to the effect of thioguanine correlates with the loss of HGPRTase activity and the resulting inability to convert thioguanine to thioguanylic acid. However, other resistance mechanisms, such as increased catabolism of TGMP by a nonspecific phosphatase, may be operative. Although not invariable, it is usual to find cross-resistance between thioguanine and its close analogue, PURINETHOL (mercaptopurine). Metabolism and Genetic Polymorphism Several published studies indicate that patients with reduced TPMT or NUDT15 activity receiving usual doses of mercaptopurine, accumulate excessive cellular concentrations of active 6-TGNs, and are at higher risk for severe myelosuppression . In a study of 1028 children with ALL, the approximate tolerated mercaptopurine dosage range for patients with TPMT and/or NUDT15 deficiency on mercaptopurine maintenance therapy (as a percentage of the planned dosage) was as follows: heterozygous for either TPMT or NUDT15, 50-90%; heterozygous for both TPMT and NUDT15, 30-50%; homozygous for either TPMT or NUDT15, 5-10%. Approximately 0.3% (1:300) of patients of European or African ancestry have two loss-of-function alleles of the TPMT gene and have little or no TPMT activity (homozygous deficient or poor metabolizers), and approximately 10% of patients have one loss-of-function TPMT allele leading to intermediate TPMT activity (heterozygous deficient or intermediate metabolizers). The TPMT*2, TPMT*3A, and TPMT*3C alleles account for about 95% of individuals with reduced levels of TPMT activity. NUDT15 deficiency is detected in <1% of patients of European or African ancestry. Among patients of East Asian ancestry (i.e., Chinese, Japanese, Vietnamese), 2% have two loss-of-function alleles of the NUDT15 gene, and approximately 21% have one loss-of-function allele. The p.R139C variant of NUDT15 (present on the *2 and *3 alleles) is the most commonly observed, but other less common loss-of-function NUDT15 alleles have been observed. Consider all clinical information when interpreting results from phenotypic testing used to determine the level of thiopurine nucleotides or TPMT activity in erythrocytes, since some coadministered drugs can influence measurement of TPMT activity in blood, and blood from recent transfusions will misrepresent a patient’s actual TPMT activity."],"indications_and_usage":["INDICATIONS AND USAGE a) Acute Nonlymphocytic Leukemias TABLOID brand Thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. However, it is not recommended for use during maintenance therapy or similar long-term continuous treatments due to the high risk of liver toxicity (see WARNINGS and ADVERSE REACTIONS). The response to this agent depends upon the age of the patient (younger patients faring better than older) and whether thioguanine is used in previously treated or previously untreated patients. Reliance upon thioguanine alone is seldom justified for initial remission induction of acute nonlymphocytic leukemias because combination chemotherapy including thioguanine results in more frequent remission induction and longer duration of remission than thioguanine alone. b) Other Neoplasms TABLOID brand Thioguanine is not effective in chronic lymphocytic leukemia, Hodgkin’s lymphoma, multiple myeloma, or solid tumors. Although thioguanine is one of several agents with activity in the treatment of the chronic phase of chronic myelogenous leukemia, more objective responses are observed with MYLERAN ® (busulfan), and therefore busulfan is usually regarded as the preferred drug."],"information_for_patients":["Information for Patients Patients should be informed that the major toxicities of thioguanine are related to myelosuppression, hepatotoxicity, and gastrointestinal toxicity. Patients should never be allowed to take the drug without medical supervision and should be advised to consult their physician if they experience fever, sore throat, jaundice, nausea, vomiting, signs of local infection, bleeding from any site, or symptoms suggestive of anemia. Women of childbearing potential should be advised to avoid becoming pregnant."],"spl_unclassified_section":["CAUTION TABLOID brand Thioguanine is a potent drug. It should not be used unless a diagnosis of acute nonlymphocytic leukemia has been adequately established and the responsible physician is knowledgeable in assessing response to chemotherapy."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION TABLOID brand Thioguanine is administered orally. The dosage which will be tolerated and effective varies according to the stage and type of neoplastic process being treated. Because the usual therapies for adult and pediatric acute nonlymphocytic leukemias involve the use of thioguanine with other agents in combination, physicians responsible for administering these therapies should be experienced in the use of cancer chemotherapy and in the chosen protocol. Patients with homozygous deficiency of either TPMT or NUDT15 enzyme typically require 10% or less of the standard thioguanine dosage. Reduce initial dosage in patients who are known to have homozygous TPMT or NUDT15 deficiency. Most of the patients with heterozygous TPMT or NUDT15 deficiency tolerate recommended thioguanine doses, but some require dose reduction based on toxicities. Patients who are heterozygous for both TPMT and NUDT15 may require more substantial dosage reduction. Reduce the dosage based on tolerability. Ninety-six (59%) of 163 pediatric patients with previously untreated acute nonlymphocytic leukemia obtained complete remission with a multiple-drug protocol including thioguanine, prednisone, cytarabine, cyclophosphamide, and vincristine. Remission was maintained with daily thioguanine, 4-day pulses of cytarabine and cyclophosphamide, and a single dose of vincristine every 28 days. The median duration of remission was 11.5 months. Fifty-three percent of previously untreated adults with acute nonlymphocytic leukemias attained remission following use of the combination of thioguanine and cytarabine according to a protocol developed at The Memorial Sloan-Kettering Cancer Center. A median duration of remission of 8.8 months was achieved with the multiple-drug maintenance regimen which included thioguanine. On those occasions when single-agent chemotherapy with thioguanine may be appropriate, the usual initial dosage for pediatric patients and adults is approximately 2 mg/kg of body weight per day. If, after 4 weeks on this dosage, there is no clinical improvement and no leukocyte or platelet depression, the dosage may be cautiously increased to 3 mg/kg/day. The total daily dose may be given at one time. The dosage of thioguanine used does not depend on whether or not the patient is receiving ZYLOPRIM (allopurinol); this is in contradistinction to the dosage reduction which is mandatory when PURINETHOL ( mercaptopurine ) or IMURAN (azathioprine) is given simultaneously with allopurinol . Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1-8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate."],"spl_product_data_elements":["TABLOID thioguanine THIOGUANINE THIOGUANINE ANHYDROUS ACACIA LACTOSE MONOHYDRATE MAGNESIUM STEARATE STARCH, POTATO STEARIC ACID off-white T40"],"package_label_principal_display_panel":["Principal Display Panel NDC 80725-630-25 TABLOID® brand THIOGUANINE Each scored tablet contains 40 mg R x only 25 Tablets carton label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility In view of its action on cellular DNA, thioguanine is potentially mutagenic and carcinogenic, and consideration should be given to the theoretical risk of carcinogenesis when thioguanine is administered (see WARNINGS)."]},"tags":[{"label":"thioguanine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin G/H synthase 1","category":"target"},{"label":"PTGS1","category":"gene"},{"label":"MAPK3","category":"gene"},{"label":"ADORA3","category":"gene"},{"label":"L01BB03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Acute myeloid leukemia, disease","category":"indication"},{"label":"Waylis Therap","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antimetabolites, Antineoplastic","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"482 reports"},{"date":"","signal":"HAEMATOTOXICITY","source":"FDA FAERS","actionTaken":"137 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"133 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"131 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"114 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"99 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"98 reports"},{"date":"","signal":"PANCYTOPENIA","source":"FDA FAERS","actionTaken":"86 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"86 reports"},{"date":"","signal":"FEBRILE BONE MARROW APLASIA","source":"FDA FAERS","actionTaken":"70 reports"}],"commonSideEffects":[{"effect":"myelosuppression","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"pancytopenia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"hyperuricemia","drugRate":"frequently","severity":"unknown"},{"effect":"nausea","drugRate":"less frequent","severity":"unknown"},{"effect":"vomiting","drugRate":"less frequent","severity":"unknown"},{"effect":"anorexia","drugRate":"less frequent","severity":"unknown"},{"effect":"stomatitis","drugRate":"less frequent","severity":"unknown"},{"effect":"intestinal necrosis","drugRate":"reported","severity":"unknown"},{"effect":"perforation","drugRate":"reported","severity":"unknown"},{"effect":"hepatic veno-occlusive disease","drugRate":"reported","severity":"unknown"},{"effect":"portal hypertension","drugRate":"reported","severity":"unknown"},{"effect":"splenomegaly","drugRate":"reported","severity":"unknown"},{"effect":"thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"esophageal varices","drugRate":"reported","severity":"unknown"},{"effect":"elevation of liver transaminases","drugRate":"reported","severity":"unknown"},{"effect":"elevation of alkaline phosphatase","drugRate":"reported","severity":"unknown"},{"effect":"elevation of gamma glutamyl transferase","drugRate":"reported","severity":"unknown"},{"effect":"jaundice","drugRate":"reported","severity":"unknown"},{"effect":"hepatoportal sclerosis","drugRate":"reported","severity":"unknown"},{"effect":"nodular regenerative hyperplasia","drugRate":"reported","severity":"unknown"},{"effect":"peliosis hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"periportal fibrosis","drugRate":"reported","severity":"unknown"},{"effect":"centrilobular hepatic necrosis","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute infectious disease","Anemia","Bleeding","Bone marrow depression","Breastfeeding (mother)","Chemotherapy-Induced Hyperuricemia","Disease of liver","Drug-induced hepatitis","Hyperbilirubinemia","Hyperuricemia","Leukopenia","Liver function tests abnormal","Neutropenic disorder","Obstruction of bile duct","Portal vein obstruction","Pregnancy, function","Thiopurine S-Methyltransferase Deficiency","Thrombocytopenic disorder"],"specialPopulations":{"Pregnancy":"Thioguanine may cause fetal harm when administered to pregnant woman. Thioguanine has been shown to be teratogenic in rats when given in doses times the human dose. When given to the rat on the 4th and 5th days of gestation, 13% of surviving placentas did not contain fetuses, and 19% of offspring were malformed or stunted. The malformations noted included generalized edema, cranial defects, and general skeletal hypoplasia.","Geriatric use":"Clinical studies of thioguanine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.","Paediatric use":"See DOSAGE AND ADMINISTRATION section."}},"trials":[],"aliases":["tioguanine"],"company":"Waylis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=thioguanine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:21.170244+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:26.650320+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:50:20.291838+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=thioguanine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:26.974107+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:50:18.613004+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:50:18.613035+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:50:28.447035+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:28.019340+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL727/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:27.670526+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA012429","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:50:18.613039+00:00"}},"allNames":"Thioguanine, thioguanine, tioguanine","offLabel":[],"synonyms":["6-Thioguanine","thioguanine","tioguanine"],"timeline":[{"date":"1966-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ASPEN GLOBAL INC to Waylis Therap"}],"aiSummary":"Thioguanine is a small molecule drug that targets Prostaglandin G/H synthase 1. It was originally developed by ASPEN GLOBAL INC and is currently owned by Waylis Therap. Thioguanine is a thioguanine drug class medication that was FDA approved in 1966 for the treatment of Acute myeloid leukemia. It has a half-life of 24.35 hours and bioavailability of 30%. Thioguanine is off-patent, meaning it is no longer protected by patents and can be manufactured by generic manufacturers.","approvals":[{"date":"1966-01-18","orphan":false,"company":"ASPEN GLOBAL INC","regulator":"FDA"}],"brandName":"Thioguanine","ecosystem":[{"indication":"Acute myeloid leukemia, disease","otherDrugs":[{"name":"aldesleukin","slug":"aldesleukin","company":"Chiron"},{"name":"azacitidine","slug":"azacitidine","company":"Celgene"},{"name":"cytarabine","slug":"cytarabine","company":""},{"name":"daunorubicin","slug":"daunorubicin","company":""}],"globalPrevalence":800000}],"mechanism":{"target":"Prostaglandin G/H synthase 1","novelty":"Follow-on","targets":[{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"},{"gene":"MAPK3","source":"DrugCentral","target":"Mitogen-activated protein kinase 3","protein":"Mitogen-activated protein kinase 3"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"XDH","source":"DrugCentral","target":"Xanthine dehydrogenase/oxidase","protein":"Xanthine dehydrogenase/oxidase"},{"gene":"HPRT1","source":"DrugCentral","target":"Hypoxanthine-guanine phosphoribosyltransferase","protein":"Hypoxanthine-guanine phosphoribosyltransferase"},{"gene":"IMPDH1","source":"DrugCentral","target":"Inosine-5'-monophosphate dehydrogenase 1","protein":"Inosine-5'-monophosphate dehydrogenase 1"},{"gene":"IMPDH2","source":"DrugCentral","target":"Inosine-5'-monophosphate dehydrogenase 2","protein":"Inosine-5'-monophosphate dehydrogenase 2"},{"gene":"ABCC4","source":"DrugCentral","target":"Multidrug resistance-associated protein 4","protein":"Multidrug resistance-associated protein 4"},{"gene":"ABCC5","source":"DrugCentral","target":"Multidrug resistance-associated protein 5","protein":"Multidrug resistance-associated protein 5"}],"modality":"Small Molecule","drugClass":"thioguanine","explanation":"","oneSentence":"","technicalDetail":"Thioguanine exerts its effects by competitively inhibiting the enzyme Prostaglandin G/H synthase 1, also known as cyclooxygenase-1 (COX-1), which is involved in the conversion of arachidonic acid to prostaglandin H2, a key step in the production of prostaglandins."},"commercial":{"launchDate":"1966","_launchSource":"DrugCentral (FDA 1966-01-18, ASPEN GLOBAL INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2632","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=thioguanine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=thioguanine","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:52:52.303762","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:31.221439+00:00","fieldsConflicting":3,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"mercaptopurine","drugSlug":"mercaptopurine","fdaApproval":"1953-09-11","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cladribine","drugSlug":"cladribine","fdaApproval":"1993-02-26","patentExpiry":"Sep 10, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fludarabine phosphate","drugSlug":"fludarabine-phosphate","fdaApproval":"1991-04-18","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clofarabine","drugSlug":"clofarabine","fdaApproval":"2004-12-28","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"nelarabine","drugSlug":"nelarabine","fdaApproval":"2005-10-28","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"thioguanine","indications":{"approved":[{"name":"Acute myeloid leukemia, disease","source":"DrugCentral","snomedId":91861009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":800000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"}],"offLabel":[{"name":"Acute lymphoid leukemia","source":"DrugCentral","drugName":"thioguanine","evidenceCount":423,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Waylis Therap","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"mercaptopurine","brandName":"mercaptopurine","genericName":"mercaptopurine","approvalYear":"1953","relationship":"same-class"},{"drugId":"cladribine","brandName":"cladribine","genericName":"cladribine","approvalYear":"1993","relationship":"same-class"},{"drugId":"fludarabine-phosphate","brandName":"fludarabine phosphate","genericName":"fludarabine phosphate","approvalYear":"1991","relationship":"same-class"},{"drugId":"clofarabine","brandName":"clofarabine","genericName":"clofarabine","approvalYear":"2004","relationship":"same-class"},{"drugId":"nelarabine","brandName":"nelarabine","genericName":"nelarabine","approvalYear":"2005","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT06124157","phase":"PHASE2","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":222,"completionDate":"2030-12-01"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":["Leukemia, Acute Lymphoblastic"],"enrollment":6430,"completionDate":"2033-06"},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":["Leukemia"],"enrollment":171,"completionDate":"2026-03-03"},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Central Nervous System Leukemia","Mixed Phenotype Acute Leukemia","Testicular Leukemia"],"enrollment":5951,"completionDate":"2032-03-31"},{"nctId":"NCT03150693","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2017-09-20","conditions":["B Acute Lymphoblastic Leukemia"],"enrollment":310,"completionDate":"2027-08"},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":["T-cell Acute Lymphoblastic Leukemia","T-cell Lymphoma","Mixed Phenotype Acute Leukemia"],"enrollment":100,"completionDate":"2033-12"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":128,"completionDate":"2034-05"},{"nctId":"NCT05276284","phase":"PHASE1,PHASE2","title":"Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy","status":"COMPLETED","sponsor":"Kristoffer Rohrberg","startDate":"2022-09-01","conditions":["Solid Tumor, Adult","Metastatic Cancer"],"enrollment":18,"completionDate":"2025-09-01"},{"nctId":"NCT03571321","phase":"PHASE1","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2019-05-28","conditions":["Acute Lymphoblastic Leukemia","ALL, Childhood","ALL"],"enrollment":15,"completionDate":"2027-09-05"},{"nctId":"NCT07072585","phase":"PHASE2,PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":["Stage II T Lymphoblastic Leukemia/Lymphoma","Stage III T Lymphoblastic Leukemia/Lymphoma","Stage IV T Lymphoblastic Leukemia/Lymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1708,"completionDate":"2035-09-01"},{"nctId":"NCT03117751","phase":"PHASE2,PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":["Acute Lymphoblastic Leukemia","Acute Lymphoblastic Lymphoma"],"enrollment":790,"completionDate":"2028-09-30"},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":["Recurrent B Acute Lymphoblastic Leukemia"],"enrollment":669,"completionDate":"2026-09-16"},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":["Adult T Acute Lymphoblastic Leukemia","Ann Arbor Stage II Adult Lymphoblastic Lymphoma","Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","Ann Arbor Stage III Adult Lymphoblastic Lymphoma","Ann Arbor Stage III Childhood Lymphoblastic Lymphoma","Ann Arbor Stage IV Adult Lymphoblastic Lymphoma","Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma","Childhood T Acute Lymphoblastic Leukemia"],"enrollment":847,"completionDate":"2026-09-16"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT02521493","phase":"PHASE3","title":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-12-23","conditions":["Acute Myeloid Leukemia","Down Syndrome","Myelodysplastic Syndrome","Myeloid Leukemia Associated With Down Syndrome","Myeloproliferative Neoplasm"],"enrollment":280,"completionDate":"2026-06-30"},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":1895,"completionDate":"2025-03-31"},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":["Acute Lymphoblastic Leukemia, Pediatric"],"enrollment":5000,"completionDate":"2028-07-14"},{"nctId":"NCT01190930","phase":"PHASE3","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2010-08-09","conditions":["Acute Lymphoblastic Leukemia","Adult B Lymphoblastic Lymphoma","Ann Arbor Stage I B Lymphoblastic Lymphoma","Ann Arbor Stage II B Lymphoblastic Lymphoma","Childhood B Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Childhood B Lymphoblastic Lymphoma","Down Syndrome","Hypodiploid B Acute Lymphoblastic Leukemia","Philadelphia Chromosome Positive"],"enrollment":9350,"completionDate":"2028-03-31"},{"nctId":"NCT06351306","phase":"PHASE2","title":"DEC-C and Thioguanine for R/R AML","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-04-01","conditions":["Acute Myeloid Leukemia"],"enrollment":0,"completionDate":"2024-04-01"},{"nctId":"NCT04043494","phase":"PHASE3","title":"International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"University Hospital Muenster","startDate":"2019-08-23","conditions":["Lymphoblastic Lymphoma, Childhood"],"enrollment":683,"completionDate":"2027-11-22"},{"nctId":"NCT02828358","phase":"PHASE2","title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-01","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia"],"enrollment":78,"completionDate":"2024-12-31"},{"nctId":"NCT01228331","phase":"PHASE2,PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":["Leukemia"],"enrollment":745,"completionDate":"2024-11-20"},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":["Inflammatory Disease","Disease Crohn","Bowel Disease"],"enrollment":158,"completionDate":"2025-12"},{"nctId":"NCT06210750","phase":"PHASE2","title":"Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-09","conditions":["T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma"],"enrollment":0,"completionDate":"2026-09-22"},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":["B Lymphoblastic Leukemia"],"enrollment":500,"completionDate":"2030-03"},{"nctId":"NCT04904653","phase":"PHASE4","title":"The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage","status":"RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2021-11-08","conditions":["Hemopatch","Breast Cancer","Axillary Lymphadenectomy"],"enrollment":118,"completionDate":"2024-12"},{"nctId":"NCT04845035","phase":"PHASE2","title":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2024-01","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":0,"completionDate":"2029-01"},{"nctId":"NCT06211452","phase":"PHASE3","title":"Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Grupo Argentino de Tratamiento de la Leucemia Aguda","startDate":"2007-08-01","conditions":["AML","Pediatric AML"],"enrollment":258,"completionDate":"2015-12-21"},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":["Acute Myeloid Leukemia","Leukemia, Acute Myeloid","Myeloid Leukemia, Acute","Leukemia, Myeloid, Acute","Acute Myelogenous Leukemia","Leukemia, Acute Myelogenous","Myelogenous Leukemia, Acute","AML","Bone Marrow Transplant"],"enrollment":153,"completionDate":"2026-12"},{"nctId":"NCT00002514","phase":"PHASE3","title":"Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-07","conditions":["Leukemia"],"enrollment":1929,"completionDate":""},{"nctId":"NCT00005585","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-04","conditions":["Leukemia"],"enrollment":838,"completionDate":""},{"nctId":"NCT00005596","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-04","conditions":["Leukemia"],"enrollment":1076,"completionDate":"2007-07"},{"nctId":"NCT00199056","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)","status":"COMPLETED","sponsor":"Goethe University","startDate":"1999-10","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":225,"completionDate":"2005-12"},{"nctId":"NCT00199069","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)","status":"COMPLETED","sponsor":"Goethe University","startDate":"1993-04","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":720,"completionDate":"2001-05"},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":600,"completionDate":"2022-03-26"},{"nctId":"NCT00198991","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-04","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":1883,"completionDate":"2013-06-30"},{"nctId":"NCT05440773","phase":"NA","title":"Emptying Malaria Reservoirs to Accelerate Malaria Elimination in High Transmission Settings","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2023-04","conditions":["Asymptomatic Malaria"],"enrollment":112,"completionDate":"2024-02"},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":["Recurrent Acute Leukemia of Ambiguous Lineage","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Acute Leukemia of Ambiguous Lineage"],"enrollment":34,"completionDate":"2021-05-13"},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":["Lymphoblastic Lymphoma"],"enrollment":23,"completionDate":"2022-05-31"},{"nctId":"NCT01117441","phase":"PHASE3","title":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-06","conditions":["Leukemia"],"enrollment":6136,"completionDate":"2021-12-31"},{"nctId":"NCT00369317","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":["Childhood Acute Basophilic Leukemia","Childhood Acute Eosinophilic Leukemia","Childhood Acute Erythroleukemia (M6)","Childhood Acute Megakaryocytic Leukemia (M7)","Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)","Childhood Acute Monoblastic Leukemia (M5a)","Childhood Acute Monocytic Leukemia (M5b)","Childhood Acute Myeloblastic Leukemia With Maturation (M2)","Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","Childhood Acute Myelomonocytic Leukemia (M4)","Childhood Myelodysplastic Syndromes","de Novo Myelodysplastic Syndromes","Secondary Acute Myeloid Leukemia","Secondary Myelodysplastic Syndromes","Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies"],"enrollment":205,"completionDate":"2021-12-31"},{"nctId":"NCT01156883","phase":"NA","title":"Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-04","conditions":["Leukemia"],"enrollment":76,"completionDate":"2017-10-31"},{"nctId":"NCT00558519","phase":"PHASE2","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2008-03-12","conditions":["Leukemia"],"enrollment":318,"completionDate":""},{"nctId":"NCT00103285","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-04-11","conditions":["Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia"],"enrollment":5377,"completionDate":"2021-03-31"},{"nctId":"NCT00075725","phase":"PHASE3","title":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2003-12-29","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia"],"enrollment":3154,"completionDate":"2021-03-31"},{"nctId":"NCT00671034","phase":"PHASE3","title":"Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-07-21","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia"],"enrollment":166,"completionDate":"2021-03-31"},{"nctId":"NCT00866307","phase":"PHASE1","title":"Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-02-23","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Childhood B Acute Lymphoblastic Leukemia"],"enrollment":104,"completionDate":"2021-03-31"},{"nctId":"NCT02281799","phase":"PHASE4","title":"Thiopurine Induced Pancreatitis in IBD Patients","status":"WITHDRAWN","sponsor":"Shaare Zedek Medical Center","startDate":"2015-03","conditions":["Pancreatitis","Inflammatory Bowel Diseases"],"enrollment":0,"completionDate":"2018-01"},{"nctId":"NCT00439296","phase":"PHASE1,PHASE2","title":"ABT-751 With Chemotherapy for Relapsed Pediatric ALL","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2006-05-22","conditions":["Recurrent Pediatric ALL","Relapsed Pediatric ALL","Acute Lymphoblastic Leukemia","Refractory Pediatric ALL"],"enrollment":9,"completionDate":"2009-09-23"},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":["Adverse Drug Reaction"],"enrollment":4465,"completionDate":"2019-05-03"},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":["Urothelial Carcinoma","Bladder Cancer","Urinary Bladder Neoplasms"],"enrollment":8,"completionDate":"2019-10-23"},{"nctId":"NCT02912676","phase":"PHASE1,PHASE2","title":"Thiopurine EnhAnced Maintenance Therapy","status":"COMPLETED","sponsor":"Kjeld Schmiegelow","startDate":"2016-10","conditions":["Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":30,"completionDate":"2020-04"},{"nctId":"NCT00866749","phase":"PHASE2","title":"Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09-12","conditions":["Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"enrollment":120,"completionDate":"2018-07-26"},{"nctId":"NCT00004228","phase":"PHASE3","title":"Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-06","conditions":["Lymphoma"],"enrollment":393,"completionDate":"2015-03-31"},{"nctId":"NCT00550992","phase":"NA","title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","status":"UNKNOWN","sponsor":"Dutch Childhood Oncology Group","startDate":"2006-01","conditions":["Leukemia"],"enrollment":445,"completionDate":""},{"nctId":"NCT02419469","phase":"PHASE2","title":"Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-11-13","conditions":["Leukemia","Precursor-B Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Lymphoma"],"enrollment":1,"completionDate":"2017-06-22"},{"nctId":"NCT02660762","phase":"PHASE2","title":"Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":["Leukaemia,Lymphoblastic"],"enrollment":100,"completionDate":"2019-01"},{"nctId":"NCT02598908","phase":"","title":"An EQA Scheme for TPMT Activity and Thiopurine Metabolites","status":"UNKNOWN","sponsor":"Sandwell & West Birmingham Hospitals NHS Trust","startDate":"2017-02-24","conditions":["External Quality Control","Thiopurine S-methyl Transferase (TPMT)"],"enrollment":40,"completionDate":"2022-02-24"},{"nctId":"NCT00002744","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-05","conditions":["Leukemia"],"enrollment":1970,"completionDate":"2007-03"},{"nctId":"NCT02141100","phase":"PHASE1,PHASE2","title":"Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma","status":"WITHDRAWN","sponsor":"Kjeld Schmiegelow","startDate":"2014-07","conditions":["Non-Hodgkin Lymphoma"],"enrollment":0,"completionDate":"2016-10"},{"nctId":"NCT02894645","phase":"PHASE4","title":"Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2008-10","conditions":["Acute Lymphoblastic Leukemia (ALL)"],"enrollment":500,"completionDate":""},{"nctId":"NCT00005945","phase":"PHASE3","title":"Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-06","conditions":["Leukemia"],"enrollment":3054,"completionDate":"2008-06"},{"nctId":"NCT00588536","phase":"PHASE2","title":"Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1995-01","conditions":["Langerhans Cell Histiocytosis"],"enrollment":5,"completionDate":"2009-06"},{"nctId":"NCT00109837","phase":"PHASE2","title":"S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2005-04","conditions":["Leukemia"],"enrollment":79,"completionDate":"2014-11"},{"nctId":"NCT00002665","phase":"PHASE2","title":"SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1995-07","conditions":["Leukemia","Neutropenia","Thrombocytopenia"],"enrollment":50,"completionDate":"2003-12"},{"nctId":"NCT00613457","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2000-09","conditions":["Leukemia"],"enrollment":2039,"completionDate":"2006-07"},{"nctId":"NCT00004056","phase":"PHASE1","title":"Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-10","conditions":["Leukemia"],"enrollment":35,"completionDate":"2007-03"},{"nctId":"NCT00003671","phase":"PHASE2","title":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1998-12","conditions":["Leukemia"],"enrollment":59,"completionDate":"2009-02"},{"nctId":"NCT00002590","phase":"PHASE2","title":"Combination Chemotherapy in Treating Children With Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1994-07","conditions":["Lymphoma"],"enrollment":221,"completionDate":"2007-03"},{"nctId":"NCT00176462","phase":"PHASE2","title":"CINJALL: Treatment for Children With Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2001-02","conditions":["Acute Lymphocytic Leukemia"],"enrollment":60,"completionDate":"2008-09"},{"nctId":"NCT00184041","phase":"PHASE2","title":"Intensified Post Remission Therapy Containing PEG-Asparaginase","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2004-07","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":47,"completionDate":"2012-12"},{"nctId":"NCT00005603","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2000-03","conditions":["Leukemia"],"enrollment":276,"completionDate":""},{"nctId":"NCT00022126","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2002-11","conditions":["Leukemia"],"enrollment":6,"completionDate":"2006-04"},{"nctId":"NCT00002658","phase":"PHASE3","title":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"1994-01","conditions":["Leukemia","Neutropenia"],"enrollment":2000,"completionDate":""},{"nctId":"NCT00003423","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"United Kingdom Children's Cancer Study Group","startDate":"1995-05","conditions":["Lymphoma"],"enrollment":100,"completionDate":""},{"nctId":"NCT00005823","phase":"PHASE3","title":"Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Leukemia Research Fund","startDate":"1998-12","conditions":["Leukemia","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasms"],"enrollment":2000,"completionDate":"2007-12"},{"nctId":"NCT00003437","phase":"PHASE3","title":"Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"1997-01","conditions":["Leukemia"],"enrollment":1800,"completionDate":""},{"nctId":"NCT00002701","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1995-10","conditions":["Leukemia"],"enrollment":750,"completionDate":""},{"nctId":"NCT00002531","phase":"PHASE2","title":"Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"1993-01","conditions":["Leukemia"],"enrollment":0,"completionDate":""},{"nctId":"NCT00002944","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Progressive Brain Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1997-04","conditions":["Brain Tumors","Central Nervous System Tumors"],"enrollment":428,"completionDate":"2012-04"},{"nctId":"NCT00343369","phase":"NA","title":"Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2003-01","conditions":["Leukemia"],"enrollment":550,"completionDate":""},{"nctId":"NCT00002812","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-09","conditions":["Leukemia"],"enrollment":2078,"completionDate":""},{"nctId":"NCT00002816","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-12","conditions":["Leukemia"],"enrollment":120,"completionDate":"2006-04"},{"nctId":"NCT00275106","phase":"PHASE3","title":"Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2004-09","conditions":["Lymphoma"],"enrollment":600,"completionDate":"2012-08"},{"nctId":"NCT00003593","phase":"PHASE3","title":"Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-06","conditions":["Leukemia","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasms"],"enrollment":254,"completionDate":"2012-04"},{"nctId":"NCT00430118","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2000-07","conditions":["Leukemia"],"enrollment":4559,"completionDate":"2012-01"},{"nctId":"NCT00002798","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-08","conditions":["Childhood Acute Erythroleukemia (M6)","Childhood Acute Megakaryocytic Leukemia (M7)","Childhood Acute Monoblastic Leukemia (M5a)","Childhood Acute Monocytic Leukemia (M5b)","Childhood Acute Myeloblastic Leukemia With Maturation (M2)","Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","Childhood Acute Myelomonocytic Leukemia (M4)","Childhood Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia","de Novo Myelodysplastic Syndromes","Refractory Anemia","Refractory Anemia With Excess Blasts","Refractory Anemia With Excess Blasts in Transformation","Refractory Anemia With Ringed Sideroblasts","Secondary Myelodysplastic Syndromes","Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies"],"enrollment":880,"completionDate":""},{"nctId":"NCT00016302","phase":"NA","title":"Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":["T-cell Childhood Acute Lymphoblastic Leukemia","Untreated Childhood Acute Lymphoblastic Leukemia"],"enrollment":100,"completionDate":""},{"nctId":"NCT00266136","phase":"PHASE3","title":"Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"1999-06","conditions":["Acute Myeloid Leukemia"],"enrollment":3500,"completionDate":"2012-10"},{"nctId":"NCT00849368","phase":"PHASE1","title":"Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2009-01","conditions":["Inflammatory Bowel Disease"],"enrollment":6,"completionDate":"2011-09"},{"nctId":"NCT00504660","phase":"PHASE2","title":"6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":["Anaplastic Glioma of Brain","Glioblastoma Multiforme","Brain Cancer"],"enrollment":75,"completionDate":"2010-08"},{"nctId":"NCT00186966","phase":"PHASE3","title":"Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Dutch Childhood Oncology Group","startDate":"2002-03","conditions":["Acute Myeloid Leukemia"],"enrollment":394,"completionDate":"2010-09"},{"nctId":"NCT00003728","phase":"PHASE3","title":"Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-12","conditions":["Leukemia","Lymphoma"],"enrollment":1500,"completionDate":""},{"nctId":"NCT00199017","phase":"PHASE4","title":"German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2004-04","conditions":["Lymphoma, Lymphoblastic"],"enrollment":75,"completionDate":""},{"nctId":"NCT00199004","phase":"PHASE4","title":"Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2004-04","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":60,"completionDate":"2009-03"},{"nctId":"NCT00002517","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1993-03","conditions":["Leukemia","Myelodysplastic Syndromes"],"enrollment":0,"completionDate":""},{"nctId":"NCT00764907","phase":"PHASE3","title":"Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"University Hospital, Motol","startDate":"2002-11","conditions":["Leukemia"],"enrollment":4000,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"TABLOID"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147080","MMSL":"2109","NDDF":"002652","UNII":"FTK8U1GZNX","VUID":"4018777","CHEBI":"CHEBI:9555","VANDF":"4018777","RXNORM":"10485","UMLSCUI":"C0039902","chemblId":"CHEMBL727","ChEMBL_ID":"CHEMBL727","KEGG_DRUG":"D06109","DRUGBANK_ID":"DB00352","PDB_CHEM_ID":"DX4","PUBCHEM_CID":"2723601","SNOMEDCT_US":"387407006","IUPHAR_LIGAND_ID":"6845","SECONDARY_CAS_RN":"5580-03-0","MESH_DESCRIPTOR_UI":"D013866"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Aspen Global Inc.","brandName":"TABLOID","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1966-","companyName":"Aspen Global Inc","relationship":"Original Developer"},{"period":"present","companyName":"Waylis Therap","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"24.35 hours","clearance":"15.4 mL/min/kg","bioavailability":"30%","volumeOfDistribution":"2.89 L/kg"},"publicationCount":3566,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01BB03","allCodes":["L01BB03"]},"biosimilarFilings":[],"originalDeveloper":"Aspen Global Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Waylis Therap","companyId":"waylis","modality":"Small Molecule","firstApprovalDate":"1966","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1966-01-18T00:00:00.000Z","mah":"ASPEN GLOBAL INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-07-03T00:00:00.000Z","mah":"WAYLIS THERAP","brand_name_local":null,"application_number":"NDA012429"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":25,"withResults":14},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:31.221439+00:00","fieldsConflicting":3,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}